Covid-19 roundup: CDC ad­vi­so­ry com­mit­tee to dis­cuss Pfiz­er/BioN­Tech boost­ers for all adults; US buys up $1B in GSK/Vir mAbs

About a week af­ter Pfiz­er asked reg­u­la­tors to ex­pand its Covid-19 boost­er shot EUA to in­clude all adults, the CDC’s Ad­vi­so­ry Com­mit­tee on Im­mu­niza­tion Prac­tices has sched­uled a meet­ing to dis­cuss the idea.

ACIP will meet this Fri­day, and is ex­pect­ed to give an of­fi­cial rec­om­men­da­tion soon af­ter, The As­so­ci­at­ed Press re­port­ed on Tues­day.

Pfiz­er and BioN­Tech’s boost­er shot is cur­rent­ly au­tho­rized for those 65 years and old­er, or at high-risk of a Covid in­fec­tion, in­clud­ing health care work­ers and oth­ers with oc­cu­pa­tion­al haz­ards. Be­fore de­cid­ing on those lim­i­ta­tions, the FDA’s ad­vi­so­ry com­mit­tee on Vac­cines and Re­lat­ed Bi­o­log­i­cal Prod­ucts (VRB­PAC) round­ly re­ject­ed Pfiz­er/BioN­Tech boost­er shots for all in­di­vid­u­als old­er than 16 by a 16-2 vote.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.